CADENCE KIM

Allopathic & Osteopathic Physicians|Urology PHILADELPHIA, PA NPI 1902809304

General Payments — all program years on this page

$2,343.70

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 107
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $459.32 across 20 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $459.3220

By paying entity

Latest program year (PY2024) · sorted by reported total.

By program year

Program yearAmountRecords
2018 $142.445
2019 $272.1214
2020 $350.8217
2021 $438.4519
2022 $293.7714
2023 $386.7818
2024 $459.3220

Records — PY2024 (20)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1139273622 Astellas Pharma US Inc $27.74 07/30/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1139290496 Astellas Pharma US Inc $34.86 01/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1139312398 Astellas Pharma US Inc $24.36 01/11/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1139318300 Astellas Pharma US Inc $21.57 03/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1139334716 Astellas Pharma US Inc $3.28 05/15/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1139389862 Astellas Pharma US Inc $27.23 09/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1139413357 Astellas Pharma US Inc $20.95 10/22/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1139434664 Astellas Pharma US Inc $23.99 12/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1139436104 Astellas Pharma US Inc $32.72 12/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1139436110 Astellas Pharma US Inc $4.08 12/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1148874530 Sumitomo Pharma America, Inc. $22.51 04/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1148874532 Sumitomo Pharma America, Inc. $19.49 12/02/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1148874534 Sumitomo Pharma America, Inc. $13.21 12/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1148874536 Sumitomo Pharma America, Inc. $29.97 12/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1151364197 180 Medical, Inc. $37.90 03/19/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1151364199 180 Medical, Inc. $28.43 07/31/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1151364201 180 Medical, Inc. $29.05 09/04/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1152533960 Myriad Genetic Laboratories, Inc. $24.98 07/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1152533962 Myriad Genetic Laboratories, Inc. $15.16 08/07/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1152533964 Myriad Genetic Laboratories, Inc. $17.84 12/18/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.